{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:40:32Z","timestamp":1790761232345,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ANR-10-LABX-62-IBEID"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vaccination is expected to change the epidemiology and management of SARS-CoV-2 epidemics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used an age-stratified compartmental model calibrated to French data to anticipate these changes and determine implications for the control of an autumn epidemic. We assumed vaccines reduce the risk of hospitalization, infection, and transmission if infected by 95%, 60%, and 50%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In our baseline scenario characterized by basic reproduction number R<jats:sub>0<\/jats:sub>=5 and a vaccine coverage of 70\u201380\u201390% among 12\u201317, 18\u201359, and \u2265 60 years old, important stress on healthcare is expected in the absence of measures. Unvaccinated adults \u226560 years old represent 3% of the population but 43% of hospitalizations. Given limited vaccine coverage, children aged 0\u201317 years old represent a third of infections and are responsible for almost half of transmissions. Unvaccinated individuals have a disproportionate contribution to transmission so that measures targeting them may help maximize epidemic control while minimizing costs for society compared to non-targeted approaches. Of all the interventions considered including repeated testing and non-pharmaceutical measures, vaccination of the unvaccinated is the most effective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>With the Delta variant, vaccinated individuals are well protected against hospitalization but remain at risk of infection and should therefore apply protective behaviors (e.g., mask-wearing). Targeting non-vaccinated individuals may maximize epidemic control while minimizing costs for society. Vaccinating children protects them from the deleterious effects of non-pharmaceutical measures. Control strategies should account for the changing SARS-CoV-2 epidemiology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02235-1","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T02:02:37Z","timestamp":1643162557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France"],"prefix":"10.1186","volume":"20","author":[{"given":"Paolo","family":"Bosetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tran Kiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Andronico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Colizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fontanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Benamouzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cauchemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"issue":"15","key":"2235_CR1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021;384(15):1412\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2101765.","journal-title":"N. Engl. J. Med."},{"issue":"10286","key":"2235_CR2","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(21)00790-X.","journal-title":"Lancet"},{"key":"2235_CR3","doi-asserted-by":"crossref","unstructured":"Harris, R. J.et al. Impact of vaccination on household transmission of SARS-COV-2 in England. (2021).","DOI":"10.1056\/NEJMc2107717"},{"key":"2235_CR4","doi-asserted-by":"crossref","unstructured":"Tran Kiem, C.et al. Short and medium-term challenges for COVID-19 vaccination: from prioritisation to the relaxation of measures. (2021).","DOI":"10.1016\/j.eclinm.2021.101001"},{"issue":"6","key":"2235_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1473-3099(21)00143-2","volume":"21","author":"S Moore","year":"2021","unstructured":"Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. Lancet Infect. Dis. 2021;21(6):793\u2013802. https:\/\/doi.org\/10.1016\/S1473-3099(21)00143-2.","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"2235_CR6","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1038\/s41467-021-23938-8","volume":"12","author":"J Viana","year":"2021","unstructured":"Viana J, van Dorp CH. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat. Commun. 2021;12(1):3674. https:\/\/doi.org\/10.1038\/s41467-021-23938-8.","journal-title":"Nat. Commun."},{"issue":"9","key":"2235_CR7","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2468-2667(21)00167-5","volume":"6","author":"K Leung","year":"2021","unstructured":"Leung K, Wu JT, Leung GM. Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study. Lancet Public Health. 2021;6(9):e674\u201382. https:\/\/doi.org\/10.1016\/S2468-2667(21)00167-5.","journal-title":"Lancet Public Health"},{"key":"2235_CR8","doi-asserted-by":"publisher","first-page":"100148","DOI":"10.1016\/j.lanepe.2021.100148","volume":"7","author":"S Galmiche","year":"2021","unstructured":"Galmiche S, Charmet T. Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study. The Lancet Regional Health - Europe. 2021;7:100148. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100148.","journal-title":"The Lancet Regional Health - Europe"},{"issue":"7","key":"2235_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133203","volume":"10","author":"G B\u00e9raud","year":"2015","unstructured":"B\u00e9raud G, Kazmercziak S. The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases. PLoS One. 2015;10(7):e0133203. https:\/\/doi.org\/10.1371\/journal.pone.0133203.","journal-title":"PLoS One"},{"issue":"6500","key":"2235_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.abc3517","volume":"369","author":"H Salje","year":"2020","unstructured":"Salje H, Tran Kiem C. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208\u201311. https:\/\/doi.org\/10.1126\/science.abc3517.","journal-title":"Science"},{"issue":"4","key":"2235_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.idnow.2020.12.007","volume":"51","author":"N Lapidus","year":"2021","unstructured":"Lapidus N, Paireau J. Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. Infectious Diseases Now. 2021;51(4):380\u20132. https:\/\/doi.org\/10.1016\/j.idnow.2020.12.007.","journal-title":"Infectious Diseases Now"},{"key":"2235_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","volume":"22","author":"KA Twohig","year":"2021","unstructured":"Twohig KA, Nyberg T. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect. Dis. 2021;22:35\u201342. https:\/\/doi.org\/10.1016\/S1473-3099(21)00475-8.","journal-title":"Lancet Infect. Dis"},{"key":"2235_CR13","doi-asserted-by":"publisher","unstructured":"Bager, P.et al. Increased Risk of Hospitalisation Associated with Infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark. SSRN Electronic Journal (2021) doi:https:\/\/doi.org\/10.2139\/ssrn.3792894.","DOI":"10.2139\/ssrn.3792894"},{"key":"2235_CR14","doi-asserted-by":"publisher","unstructured":"Bosetti P, Kiem CT, Yazdanpanah Y, Fontanet A, Lina B, Colizza V, et al. Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France. Euro Surveill. 2021;26(1). https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.26.1.2001978.","DOI":"10.2807\/1560-7917.ES.2020.26.1.2001978"},{"key":"2235_CR15","unstructured":"FitzJohn, R. ODE Generation and Integration [R package odin version 1.2.1]. (2021)."},{"key":"2235_CR16","doi-asserted-by":"publisher","unstructured":"Tartof, S. Y.et al. Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study. (2021) doi:https:\/\/doi.org\/10.2139\/ssrn.3909743.","DOI":"10.2139\/ssrn.3909743"},{"key":"2235_CR17","doi-asserted-by":"publisher","unstructured":"Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I\/501Y.V1 (B.1.1.7, variant of concern 202012\/01) in France, January to March 2021. Euro Surveill. 2021;26(9). https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.9.2100133.","DOI":"10.2807\/1560-7917.ES.2021.26.9.2100133"},{"key":"2235_CR18","unstructured":"Davies, N. G.et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, (2021)."},{"key":"2235_CR19","unstructured":"Public Health England. Investigation of SARS-CoV-2 variants of concern: variant risk assessments - Risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2).https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/992981\/10_June_2021_Risk_assessment_for_SARS-CoV-2_variant_DELTA.pdf (2021)."},{"key":"2235_CR20","doi-asserted-by":"crossref","unstructured":"Campbell, F.et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.Eurosurveillance vol. 26 (2021).","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100509"},{"issue":"2","key":"2235_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamapediatrics.2020.4573","volume":"175","author":"RM Viner","year":"2021","unstructured":"Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 2021;175(2):143\u201356. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.4573.","journal-title":"JAMA Pediatr."},{"issue":"5","key":"2235_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S1473-3099(20)30981-6","volume":"21","author":"F Li","year":"2021","unstructured":"Li F, Li YY, Liu MJ, Fang LQ, Dean NE, Wong GWK, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect. Dis. 2021;21(5):617\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(20)30981-6.","journal-title":"Lancet Infect. Dis."},{"issue":"7858","key":"2235_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","volume":"593","author":"E Volz","year":"2021","unstructured":"Volz E, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03470-x.","journal-title":"Nature"},{"key":"2235_CR24","unstructured":"YoungMinds. Coronavirus: Impact on young people with mental health needs. Survey 4: February 2021.https:\/\/youngminds.org.uk\/media\/4350\/coronavirus-report-winter.pdf (2021)."},{"issue":"10309","key":"2235_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet. 2021;398(10309):1407\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(21)02183-8.","journal-title":"The Lancet"},{"issue":"6","key":"2235_CR26","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2468-2667(21)00064-5","volume":"6","author":"N Hoz\u00e9","year":"2021","unstructured":"Hoz\u00e9 N, Paireau J, Lapidus N, Tran Kiem C, Salje H, Severi G, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. Lancet Public Health. 2021;6(6):e408\u201315. https:\/\/doi.org\/10.1016\/S2468-2667(21)00064-5.","journal-title":"Lancet Public Health"},{"issue":"22","key":"2235_CR27","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1016\/j.vaccine.2021.04.002","volume":"39","author":"AB Hogan","year":"2021","unstructured":"Hogan AB, Winskill P, Watson OJ, Walker PGT, Whittaker C, Baguelin M, et al. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. Vaccine. 2021;39(22):2995\u20133006. https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.002.","journal-title":"Vaccine"},{"key":"2235_CR28","doi-asserted-by":"crossref","unstructured":"Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first? Sci Adv. 2020;7.","DOI":"10.1101\/2020.08.14.20175257"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02235-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T13:24:42Z","timestamp":1676899482000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02235-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02235-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competeing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}